Related Organization(s)

You just read:

Frost & Sullivan Publishes Q-1 Update Coverage Report on DNA Biomedical Solutions Ltd.: Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; Target price remains unchanged.

News provided by

Frost & Sullivan

Jul 03, 2018, 05:21 ET